MedTrace Logo

Chiauranib in Combination With Chemotherapy in Patients With Ovarian Cancer

NCT03901118 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2021-03-19

No results posted yet for this study

Summary

This clinical trial will evaluate the efficacy and safety of chiauranib added to chemotherapy in patients with relapsed or refractory ovarian cancer, in the meantime, explore the pharmacokinetics characteristic after the combined treatment.

Conditions

Interventions

DRUG

chiauranib

in the phase of pilot trial, 25mg orally once daily; in the formal phase, 50mg orally once daily

DRUG

etoposide

50mg orally once daily for 21 days, 7 days off, every 28 days for a cycle, 6 cycles at most

DRUG

paclitaxel

60mg/m2, i.v infusion on day 1, 8 and 15, every 21 days for a cycle, 6 cycles at most

Sponsors & Collaborators

  • Chipscreen Biosciences, Ltd.

    lead INDUSTRY

Principal Investigators

  • Xiaohua Wu · Fudan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-01
Primary Completion
2020-12-18
Completion
2020-12-18

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03901118 on ClinicalTrials.gov